CA3080719A1 - Procedes et systemes de surveillance continue du glucose - Google Patents
Procedes et systemes de surveillance continue du glucose Download PDFInfo
- Publication number
- CA3080719A1 CA3080719A1 CA3080719A CA3080719A CA3080719A1 CA 3080719 A1 CA3080719 A1 CA 3080719A1 CA 3080719 A CA3080719 A CA 3080719A CA 3080719 A CA3080719 A CA 3080719A CA 3080719 A1 CA3080719 A1 CA 3080719A1
- Authority
- CA
- Canada
- Prior art keywords
- sensor
- glucose
- voltage
- impedance
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 398
- 239000008103 glucose Substances 0.000 title claims abstract description 398
- 238000000034 method Methods 0.000 title claims abstract description 253
- 238000012544 monitoring process Methods 0.000 title claims description 29
- 230000004927 fusion Effects 0.000 claims abstract description 184
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 164
- 230000036571 hydration Effects 0.000 claims abstract description 74
- 238000006703 hydration reaction Methods 0.000 claims abstract description 74
- 230000006641 stabilisation Effects 0.000 claims abstract description 72
- 238000011105 stabilization Methods 0.000 claims abstract description 72
- 238000004364 calculation method Methods 0.000 claims abstract description 50
- 238000000157 electrochemical-induced impedance spectroscopy Methods 0.000 claims description 319
- 238000005259 measurement Methods 0.000 claims description 179
- 230000006870 function Effects 0.000 claims description 102
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 48
- 230000007704 transition Effects 0.000 claims description 35
- 102000004877 Insulin Human genes 0.000 claims description 24
- 108090001061 Insulin Proteins 0.000 claims description 24
- 229940125396 insulin Drugs 0.000 claims description 24
- 238000003066 decision tree Methods 0.000 claims description 20
- 238000010801 machine learning Methods 0.000 claims description 13
- 238000005070 sampling Methods 0.000 claims description 13
- 238000007781 pre-processing Methods 0.000 claims description 11
- 238000012549 training Methods 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 abstract description 26
- 230000008901 benefit Effects 0.000 abstract description 10
- 238000012935 Averaging Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 description 158
- 238000012360 testing method Methods 0.000 description 140
- 230000008859 change Effects 0.000 description 105
- 238000001514 detection method Methods 0.000 description 104
- 239000012528 membrane Substances 0.000 description 67
- 238000010586 diagram Methods 0.000 description 59
- 239000000872 buffer Substances 0.000 description 45
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 41
- 229910052760 oxygen Inorganic materials 0.000 description 41
- 239000001301 oxygen Substances 0.000 description 41
- 238000013461 design Methods 0.000 description 40
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 40
- 230000008569 process Effects 0.000 description 39
- 238000003780 insertion Methods 0.000 description 38
- 230000037431 insertion Effects 0.000 description 38
- 230000007423 decrease Effects 0.000 description 35
- 230000004044 response Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 230000000875 corresponding effect Effects 0.000 description 23
- 238000002405 diagnostic procedure Methods 0.000 description 22
- 238000001802 infusion Methods 0.000 description 22
- 230000000246 remedial effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000012545 processing Methods 0.000 description 20
- 238000007920 subcutaneous administration Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 230000000630 rising effect Effects 0.000 description 18
- 238000012546 transfer Methods 0.000 description 17
- 230000001419 dependent effect Effects 0.000 description 16
- 230000010354 integration Effects 0.000 description 16
- 150000002978 peroxides Chemical class 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 238000004088 simulation Methods 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 230000001960 triggered effect Effects 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 239000003990 capacitor Substances 0.000 description 13
- 206010021143 Hypoxia Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000000737 periodic effect Effects 0.000 description 12
- 238000011088 calibration curve Methods 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 230000007774 longterm Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 10
- 238000009792 diffusion process Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000000087 stabilizing effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 238000013528 artificial neural network Methods 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000010363 phase shift Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000019420 glucose oxidase Nutrition 0.000 description 6
- 238000009499 grossing Methods 0.000 description 6
- 238000002847 impedance measurement Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000010287 polarization Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 238000012404 In vitro experiment Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 230000000887 hydrating effect Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012805 post-processing Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 101100372601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POR2 gene Proteins 0.000 description 4
- 101100099673 Zea mays TIP2-3 gene Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 101150091821 SLC3A1 gene Proteins 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006854 communication Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012774 diagnostic algorithm Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000003487 electrochemical reaction Methods 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 238000012358 sourcing Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 241001270131 Agaricus moelleri Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007175 bidirectional communication Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000027734 detection of oxygen Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000010291 electrical method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001453 impedance spectrum Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003062 neural network model Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- -1 nickel metalhydride Chemical class 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000013450 outlier detection Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/155—Devices specially adapted for continuous or multiple sampling, e.g. at predetermined intervals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Abstract
La présente invention concerne un procédé d'étalonnage facultatif d'un capteur de glucose sans étalonnage qui utilise des valeurs de courant d'électrode de travail mesuré (Isig) et des données EIS pour calculer une valeur finale de glucose obtenue par le capteur (SG). Une tension de contre-électrode (Vcntr) peut également être utilisée en tant qu'entrée. Les valeurs Isig et Vcntr brutes peuvent être prétraitées, et soumises à un filtrage passe-bas, un calcul de moyenne et/ou une génération de caractéristique peuvent être appliquées. Des valeurs SG peuvent être générées au moyen d'un ou plusieurs modèles pour prédire des calculs de SG. Une redondance complexe peut être utilisée pour tirer un bénéfice opérationnel des caractéristiques disparates de deux ou plus de deux capteurs dissemblables, ou non identiques, comprenant, par exemple, des caractéristiques relatives à l'hydratation, la stabilisation et la durabilité de tels capteurs. Des algorithmes de fusion, EIS et des circuits intégrés spécifiques à une application (ASIC) avancés peuvent être utilisés pour mettre en uvre l'utilisation de tels capteurs de glucose, dispositifs, et systèmes de capteur redondants de façon à combler les brèches entre un démarrage rapide, une longévité de capteur et une précision d'algorithmes sans étalonnage.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/840,515 US11213230B2 (en) | 2017-12-13 | 2017-12-13 | Optional sensor calibration in continuous glucose monitoring |
| US15/840,673 US11471082B2 (en) | 2017-12-13 | 2017-12-13 | Complex redundancy in continuous glucose monitoring |
| US15/840,515 | 2017-12-13 | ||
| US15/840,673 | 2017-12-13 | ||
| PCT/US2018/055845 WO2019118060A1 (fr) | 2017-12-13 | 2018-10-15 | Procédés et systèmes de surveillance continue du glucose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3080719A1 true CA3080719A1 (fr) | 2019-06-20 |
Family
ID=64100724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3080719A Pending CA3080719A1 (fr) | 2017-12-13 | 2018-10-15 | Procedes et systemes de surveillance continue du glucose |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3723606A1 (fr) |
| JP (2) | JP7309714B2 (fr) |
| KR (2) | KR102623744B1 (fr) |
| CN (1) | CN111479504A (fr) |
| AU (1) | AU2018385249B2 (fr) |
| CA (1) | CA3080719A1 (fr) |
| WO (1) | WO2019118060A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021206871A1 (fr) * | 2020-04-09 | 2021-10-14 | Medtronic Minimed, Inc. | Procédés et systèmes permettant d'atténuer la propagation d'erreur de capteur |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI724467B (zh) * | 2019-07-19 | 2021-04-11 | 國立中興大學 | 機台老化診斷方法 |
| TWI704346B (zh) * | 2019-08-02 | 2020-09-11 | 財團法人工業技術研究院 | 智慧濃度測量系統、方法及智慧濃度分析模組 |
| US11678820B2 (en) * | 2019-09-10 | 2023-06-20 | Ascensia Diabetes Care Holdings Ag | Methods and apparatus for information gathering, error detection and analyte concentration determination during continuous analyte sensing |
| US11449697B2 (en) * | 2019-09-13 | 2022-09-20 | Tektronix, Inc. | Combined higher order statistics and artificial intelligence signal analysis |
| CA3160996A1 (fr) * | 2019-11-13 | 2021-05-20 | Senseonics, Incorporated | Systeme de surveillance d'analyte dans une detection interferente |
| GB2589337A (en) * | 2019-11-27 | 2021-06-02 | Continental Automotive Gmbh | Method of determining fused sensor measurement and vehicle safety system using the fused sensor measurement |
| CN111126478B (zh) * | 2019-12-19 | 2023-07-07 | 北京迈格威科技有限公司 | 卷积神经网络训练方法、装置和电子系统 |
| CN111198545B (zh) * | 2019-12-24 | 2021-05-04 | 重庆特斯联智慧科技股份有限公司 | 一种智能建筑室内空气环境维护系统和方法 |
| US11833327B2 (en) | 2020-03-06 | 2023-12-05 | Medtronic Minimed, Inc. | Analyte sensor configuration and calibration based on data collected from a previously used analyte sensor |
| US20220117521A1 (en) * | 2020-10-20 | 2022-04-21 | eTouch Medical Inc. | Cloud system of non-invasive measuring blood glucose |
| KR102459428B1 (ko) * | 2020-12-14 | 2022-10-27 | 주식회사 아이센스 | 생체정보 측정장치의 누설전류 탐지 방법 |
| CN113317782B (zh) * | 2021-04-20 | 2022-03-22 | 港湾之星健康生物(深圳)有限公司 | 多模个性化监测的方法 |
| CN115236135B (zh) * | 2021-04-23 | 2023-08-22 | 中国石油化工股份有限公司 | 用于气体传感器的基线校准方法、控制装置和气体传感器 |
| CN113255746B (zh) * | 2021-05-14 | 2022-03-29 | 国网甘肃省电力公司经济技术研究院 | 基于决策树的新能源电动汽车退役动力电池等级筛选方法 |
| EP4380446A1 (fr) * | 2021-08-06 | 2024-06-12 | Medtrum Technologies Inc. | Capteur de micro-analyte |
| CN115372428A (zh) * | 2022-04-14 | 2022-11-22 | 深圳可孚生物科技有限公司 | 一种基于冗余电极的电化学传感器及其衰减补偿方法 |
| CN116973563B (zh) * | 2023-09-22 | 2023-12-19 | 宁波奥丞生物科技有限公司 | 一种基于正交锁相放大的免疫荧光层析测定方法及装置 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4573994A (en) | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
| US4678408A (en) | 1984-01-06 | 1987-07-07 | Pacesetter Infusion, Ltd. | Solenoid drive apparatus for an external infusion pump |
| US4685903A (en) | 1984-01-06 | 1987-08-11 | Pacesetter Infusion, Ltd. | External infusion pump apparatus |
| US4562751A (en) | 1984-01-06 | 1986-01-07 | Nason Clyde K | Solenoid drive apparatus for an external infusion pump |
| US5080653A (en) | 1990-04-16 | 1992-01-14 | Pacesetter Infusion, Ltd. | Infusion pump with dual position syringe locator |
| US5097122A (en) | 1990-04-16 | 1992-03-17 | Pacesetter Infusion, Ltd. | Medication infusion system having optical motion sensor to detect drive mechanism malfunction |
| US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
| US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
| US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
| US5482473A (en) | 1994-05-09 | 1996-01-09 | Minimed Inc. | Flex circuit connector |
| US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
| CA2666429A1 (fr) | 1998-10-08 | 2000-04-13 | Medtronic Minimed, Inc. | Systeme de surveillance par telemesure d'une caracteristique |
| US7460130B2 (en) * | 2000-09-26 | 2008-12-02 | Advantage 3D Llc | Method and system for generation, storage and distribution of omni-directional object views |
| US20170164878A1 (en) * | 2012-06-14 | 2017-06-15 | Medibotics Llc | Wearable Technology for Non-Invasive Glucose Monitoring |
| US10327685B2 (en) * | 2012-12-20 | 2019-06-25 | Becton, Dickinson And Company | System and method for using multiple sensor calibration methods |
| EP4101483A1 (fr) * | 2014-08-01 | 2022-12-14 | Becton, Dickinson and Company | Dispositif d'injection pour surveillance continue du glucose |
| US10349872B2 (en) * | 2015-12-28 | 2019-07-16 | Medtronic Minimed, Inc. | Methods, systems, and devices for sensor fusion |
| US20170181671A1 (en) * | 2015-12-28 | 2017-06-29 | Medtronic Minimed, Inc. | Sensor-unspecific calibration methods and systems |
-
2018
- 2018-10-15 WO PCT/US2018/055845 patent/WO2019118060A1/fr unknown
- 2018-10-15 KR KR1020207016915A patent/KR102623744B1/ko active IP Right Grant
- 2018-10-15 EP EP18796808.6A patent/EP3723606A1/fr active Pending
- 2018-10-15 JP JP2020532988A patent/JP7309714B2/ja active Active
- 2018-10-15 KR KR1020247000469A patent/KR20240008409A/ko active Search and Examination
- 2018-10-15 AU AU2018385249A patent/AU2018385249B2/en active Active
- 2018-10-15 CA CA3080719A patent/CA3080719A1/fr active Pending
- 2018-10-15 CN CN201880080621.1A patent/CN111479504A/zh active Pending
-
2023
- 2023-07-05 JP JP2023110795A patent/JP2023126308A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021206871A1 (fr) * | 2020-04-09 | 2021-10-14 | Medtronic Minimed, Inc. | Procédés et systèmes permettant d'atténuer la propagation d'erreur de capteur |
| US11596359B2 (en) | 2020-04-09 | 2023-03-07 | Medtronic Minimed, Inc. | Methods and systems for mitigating sensor error propagation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200097270A (ko) | 2020-08-18 |
| JP2023126308A (ja) | 2023-09-07 |
| AU2018385249A1 (en) | 2020-06-04 |
| AU2018385249B2 (en) | 2024-02-01 |
| KR102623744B1 (ko) | 2024-01-12 |
| WO2019118060A1 (fr) | 2019-06-20 |
| KR20240008409A (ko) | 2024-01-18 |
| JP2021506422A (ja) | 2021-02-22 |
| EP3723606A1 (fr) | 2020-10-21 |
| JP7309714B2 (ja) | 2023-07-18 |
| CN111479504A (zh) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202343B2 (en) | Methods, systems, and devices for calibration and optimization of glucose sensors and sensor output | |
| AU2020203049B2 (en) | Methods for continuous glucose monitoring | |
| AU2018385249B2 (en) | Methods and systems for continuous glucose monitoring | |
| AU2019203620B2 (en) | Use of electrochemical impedance spectroscopy (EIS) in continuous glucose monitoring | |
| CA3008638C (fr) | Procedes, systemes, et dispositifs de fusion de capteur | |
| CA3008640C (fr) | Systemes, dispositifs et methodes pour capteur retrospectif | |
| US20200245910A1 (en) | Methods, systems, and devices for continuous glucose monitoring | |
| CA3008647C (fr) | Procedes et systemes d'etalonnage non-specifique a un capteur | |
| US20220095964A1 (en) | Optional sensor calibration in continuous glucose monitoring | |
| US11471082B2 (en) | Complex redundancy in continuous glucose monitoring | |
| CA3078401A1 (fr) | Capteurs de glucose redondants pseudo-orthogonaux, systemes et procedes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231013 |